An economic value of the glycated hemoglobin test in diabetes mellitus type 2 diagnosis

BACKGROUND: Diagnostic of diabetes mellitus type 2 (DM2T) in time is very actual for treatment and prevention of potential complications of illness. Fasting blood glucose test (FBG) is a widely used method of primary DM2T diagnose. Glycated hemoglobin (HbA1c) test is an alternative and used more rar...

Full description

Saved in:

Bibliographic Details
Main Authors:	Marina V. Shestakova, Alexey S. Kolbin, Oleg I. Karpov, Gagik R. Galstyan, Alexander Y. Mayorov, Maria A. Arepeva, Aleksey A. Kurylev, Maxim A. Proskurin
Format:	article
Language:	EN RU
Published:	Endocrinology Research Centre 2019
Subjects:	diabetes mellitus type 2 hba1c test fasting blood glucose test health technology assessment Nutritional diseases. Deficiency diseases RC620-627
Online Access:	https://doaj.org/article/b61a566dd90c430e8f84267dbb4e70d4
Tags:	Add Tag No Tags, Be the first to tag this record!

id	oai:doaj.org-article:b61a566dd90c430e8f84267dbb4e70d4
record_format	dspace
spelling	oai:doaj.org-article:b61a566dd90c430e8f84267dbb4e70d42021-11-14T09:00:22ZAn economic value of the glycated hemoglobin test in diabetes mellitus type 2 diagnosis2072-03512072-037810.14341/DM12205https://doaj.org/article/b61a566dd90c430e8f84267dbb4e70d42019-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/12205https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378BACKGROUND: Diagnostic of diabetes mellitus type 2 (DM2T) in time is very actual for treatment and prevention of potential complications of illness. Fasting blood glucose test (FBG) is a widely used method of primary DM2T diagnose. Glycated hemoglobin (HbA1c) test is an alternative and used more rarely due to expensive. AIM: Modelling of comparative expenditures for DM2T control in cases of primary diagnostic by HbA1c test or FBG test usage in 20-years horizon. METHODS: Retrospective analysis of aggregated epidemiological Russian NATION study data in 810 patients with prediabetes and DM2T with both analysis performed, with sensitivity and specificity of each is detected. The simulation model of DM2T outcomes has been used for Health Technology assessment (direct and indirect costs of Diabetes control during 20 years). Three algorithms of the DM2T treatment were investigated for understanding of expenditures in case on diagnostic on-time and case of late verification with metformin, gliflozines, gliptins, Glucagon-like peptide-1 receptor agonists, basal insulin analogs and their combinations. RESULTS: FBG test has more negative results for DM2T diagnostics in compare with HbA1c analysis (77,4% and 36,5% accordingly). Amount of false negative results in FBG test in 3 times more often occurred in comparison with HbA1c. HbA1c test in 3 times more precisely than FBG test for carbon metabolism abnormalities detection. Diagnostic in time with HbA1c test in compare with late process of illness detection by FBG can cut common expenditures on 26,3-27,7% depending on treatment option due to macrovasular complications decreasing. Disability rate is expected decrease on 21% to 20-th year in case of diagnostic with HbA1c performing instead FBG test. CONCLUSION: HbA1c test has diagnostic advantages in compare with FBG test for primary investigation (dispanserization). Direct and indirect expenditures in average for one patient with DM2T on 20-years horizon including cost of drugs, analysis, complications, disabilities are less in case of diagnostic in time with HbA1c test in comparison with late diagnostics in case of FBG test execution.Marina V. ShestakovaAlexey S. KolbinOleg I. KarpovGagik R. GalstyanAlexander Y. MayorovMaria A. ArepevaAleksey A. KurylevMaxim A. ProskurinEndocrinology Research Centrearticlediabetes mellitus type 2hba1c testfasting blood glucose testhealth technology assessmentNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 22, Iss 6, Pp 504-514 (2019)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus type 2 hba1c test fasting blood glucose test health technology assessment Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus type 2 hba1c test fasting blood glucose test health technology assessment Nutritional diseases. Deficiency diseases RC620-627 Marina V. Shestakova Alexey S. Kolbin Oleg I. Karpov Gagik R. Galstyan Alexander Y. Mayorov Maria A. Arepeva Aleksey A. Kurylev Maxim A. Proskurin An economic value of the glycated hemoglobin test in diabetes mellitus type 2 diagnosis
description	BACKGROUND: Diagnostic of diabetes mellitus type 2 (DM2T) in time is very actual for treatment and prevention of potential complications of illness. Fasting blood glucose test (FBG) is a widely used method of primary DM2T diagnose. Glycated hemoglobin (HbA1c) test is an alternative and used more rarely due to expensive. AIM: Modelling of comparative expenditures for DM2T control in cases of primary diagnostic by HbA1c test or FBG test usage in 20-years horizon. METHODS: Retrospective analysis of aggregated epidemiological Russian NATION study data in 810 patients with prediabetes and DM2T with both analysis performed, with sensitivity and specificity of each is detected. The simulation model of DM2T outcomes has been used for Health Technology assessment (direct and indirect costs of Diabetes control during 20 years). Three algorithms of the DM2T treatment were investigated for understanding of expenditures in case on diagnostic on-time and case of late verification with metformin, gliflozines, gliptins, Glucagon-like peptide-1 receptor agonists, basal insulin analogs and their combinations. RESULTS: FBG test has more negative results for DM2T diagnostics in compare with HbA1c analysis (77,4% and 36,5% accordingly). Amount of false negative results in FBG test in 3 times more often occurred in comparison with HbA1c. HbA1c test in 3 times more precisely than FBG test for carbon metabolism abnormalities detection. Diagnostic in time with HbA1c test in compare with late process of illness detection by FBG can cut common expenditures on 26,3-27,7% depending on treatment option due to macrovasular complications decreasing. Disability rate is expected decrease on 21% to 20-th year in case of diagnostic with HbA1c performing instead FBG test. CONCLUSION: HbA1c test has diagnostic advantages in compare with FBG test for primary investigation (dispanserization). Direct and indirect expenditures in average for one patient with DM2T on 20-years horizon including cost of drugs, analysis, complications, disabilities are less in case of diagnostic in time with HbA1c test in comparison with late diagnostics in case of FBG test execution.
format	article
author	Marina V. Shestakova Alexey S. Kolbin Oleg I. Karpov Gagik R. Galstyan Alexander Y. Mayorov Maria A. Arepeva Aleksey A. Kurylev Maxim A. Proskurin
author_facet	Marina V. Shestakova Alexey S. Kolbin Oleg I. Karpov Gagik R. Galstyan Alexander Y. Mayorov Maria A. Arepeva Aleksey A. Kurylev Maxim A. Proskurin
author_sort	Marina V. Shestakova
title	An economic value of the glycated hemoglobin test in diabetes mellitus type 2 diagnosis
title_short	An economic value of the glycated hemoglobin test in diabetes mellitus type 2 diagnosis
title_full	An economic value of the glycated hemoglobin test in diabetes mellitus type 2 diagnosis
title_fullStr	An economic value of the glycated hemoglobin test in diabetes mellitus type 2 diagnosis
title_full_unstemmed	An economic value of the glycated hemoglobin test in diabetes mellitus type 2 diagnosis
title_sort	economic value of the glycated hemoglobin test in diabetes mellitus type 2 diagnosis
publisher	Endocrinology Research Centre
publishDate	2019
url	https://doaj.org/article/b61a566dd90c430e8f84267dbb4e70d4
work_keys_str_mv	AT marinavshestakova aneconomicvalueoftheglycatedhemoglobintestindiabetesmellitustype2diagnosis AT alexeyskolbin aneconomicvalueoftheglycatedhemoglobintestindiabetesmellitustype2diagnosis AT olegikarpov aneconomicvalueoftheglycatedhemoglobintestindiabetesmellitustype2diagnosis AT gagikrgalstyan aneconomicvalueoftheglycatedhemoglobintestindiabetesmellitustype2diagnosis AT alexanderymayorov aneconomicvalueoftheglycatedhemoglobintestindiabetesmellitustype2diagnosis AT mariaaarepeva aneconomicvalueoftheglycatedhemoglobintestindiabetesmellitustype2diagnosis AT alekseyakurylev aneconomicvalueoftheglycatedhemoglobintestindiabetesmellitustype2diagnosis AT maximaproskurin aneconomicvalueoftheglycatedhemoglobintestindiabetesmellitustype2diagnosis AT marinavshestakova economicvalueoftheglycatedhemoglobintestindiabetesmellitustype2diagnosis AT alexeyskolbin economicvalueoftheglycatedhemoglobintestindiabetesmellitustype2diagnosis AT olegikarpov economicvalueoftheglycatedhemoglobintestindiabetesmellitustype2diagnosis AT gagikrgalstyan economicvalueoftheglycatedhemoglobintestindiabetesmellitustype2diagnosis AT alexanderymayorov economicvalueoftheglycatedhemoglobintestindiabetesmellitustype2diagnosis AT mariaaarepeva economicvalueoftheglycatedhemoglobintestindiabetesmellitustype2diagnosis AT alekseyakurylev economicvalueoftheglycatedhemoglobintestindiabetesmellitustype2diagnosis AT maximaproskurin economicvalueoftheglycatedhemoglobintestindiabetesmellitustype2diagnosis
_version_	1718429484017778688

An economic value of the glycated hemoglobin test in diabetes mellitus type 2 diagnosis

Similar Items